Podcasts about Tempus

Concluimos la temporada escuchando las adaptaciones realizadas en los últimos años para la solemnidad del Corazón de Jesús creada a mediados del s. XIX. También habrá lugar para los cantos de la semana XIIIª del Tempus per Annum que comenzará mañana, aunque excepcionalmente y al coincidir con la conmemoración de los ss. Pedro y Pablo, dedicaremos el final del programa a diversas músicas a ellos dedicadas.Escuchar audio

Dr. Shaalan Beg and Dr. Kristen Ciombor discuss practice-changing studies in GI cancers and other novel treatment approaches that were presented at the 2025 ASCO Annual Meeting. Transcript Dr. Shaalan Beg: Hello, I'm Dr. Shaalan Beg, welcoming you to the ASCO Daily News Podcast. I'm a medical oncologist and an adjunct associate professor at UT Southwestern Medical Center in Dallas, Texas. There were some remarkable advances in gastrointestinal cancers that were presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Kristen Ciombor to discuss some exciting GI data. Dr. Ciombor is the Ingram Associate Professor of Cancer Research and a co-leader of Translational Research and the Interventional Oncology Research Program at the Vanderbilt Ingram Cancer Center. Our full disclosures are available in the transcript of this episode. Dr. Ciombor, it's great to have you on the podcast today. Dr. Kristen Ciombor: Thanks, Dr Beg. It's great to be here. Dr. Shaalan Beg: Alright, let's kick it off. Big year for GI cancers. We'll start off with LBA1. This was the ATOMIC study sponsored by NCI and the National Clinical Trials Network (NCTN) and the Alliance group. This is a randomized study of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for stage III mismatch repair deficient colorectal cancer. Dr. Kristen Ciombor: I think this study was really definitely practice-changing, as you can tell because it was a Plenary. But I do have some concerns in terms of how we're actually going to implement this and whether this is the final answer in this disease subtype. So, as you said, the patients were enrolled with stage III resected mismatch repair deficient colon cancer, and then they were randomized to either modified FOLFOX6 with or without atezolizumab. And that's where it starts to become interesting because not many of us give FOLFOX for 6 months like was done in this study. Obviously, the study was done over many years, so that was part of that answer, but also the patients received atezolizumab for a total of 12 months. So the question, I think, that comes from this abstract is, is this practical and is this the final answer? I do think that this is practice-changing, and I will be talking to my patients with resected mismatch repair deficient colon cancer about FOLFOX plus atezolizumab. I think the big question is, do these patients need chemotherapy? And can we do a neoadjuvant approach instead? And that's where we don't have all the answers yet. Dr. Shaalan Beg: Yeah, but it has been great to see immunotherapy make its way into the adjuvant space after having made such a big impact in the metastatic space, but still some unanswered questions in terms of the need for chemotherapy and then the duration of therapy, which I guess we'll have to stay tuned in for the next couple of years to to get a lot of those questions answered. Dr. Kristen Ciombor: Yeah, but a big congratulations to the study team, to the NCTN, the NCI. I mean, this is really a great example of federally funded research that needs to continue. So, great job by the study team. The DFS 10% difference is really very large and certainly a practice-changing study. Dr. Shaalan Beg: Yeah, and and sticking with colon cancer, and and this another federally funded study, but this time funded by a Canadian cancer clinical trials group was LBA3510. This is the CHALLENGE study. It's a randomized phase 3 trial of the impact of a structured exercise program on disease-free survival for stage III or high-risk stage II colon cancer. This study got a lot of buzz, a lot of mainstream press coverage, and a lot of discussions on what that means for us for the patients who we're going to be seeing next week in our clinic. What was your takeaway? Dr. Kristen Ciombor: Yeah, this is a really interesting study, and I was so glad to see it presented because this partially answers one of the questions that patients always have for us in clinic, right? You know, once they've completed their standard chemotherapy and surgery, what else can they do to help prevent recurrence? And so we've always known and sort of extrapolated that healthy lifestyle habits are good, but now we have data, particularly in these patients. Most of them were stage III colon cancer patients, those had high-risk stage II cancer. And basically, the goal was to increase their physical activity by at least 10 MET hours per week. So, my big question, of course, as I came into this presentation was, “Okay, what does that mean exactly? How does that translate to real life?” And really what the author presented and explained was that basically most patients could hit their target by adding a 45- to 60-minute brisk walk 3 to 4 times a week. So I think this is very approachable.  Now, in the confines of the study, this was a structured exercise program, so it wasn't just patients doing this on their own. But I do think kind of extrapolating from that, that this is very achievable for most patients. And not only did this prevent recurrence of their prior cancer, but actually the rate of new primary cancer diagnoses, was less, which is really interesting, especially in the breast and prostate cancer. So this was a really interesting, and I think practice-changing study as well, especially given that this is something that most patients can do. Dr. Shaalan Beg: Yeah, and there was a lot of discussion in the hallways after the presentation in terms of how this really changes our existing practice because most folks already recommend exercise as a way for improving outcomes in cancer patients. So we've already been doing that. Now we have some data on how much it can impact the benefit. But there was some discussion about what the actual degree of impact was. There was a drop-off rate in terms of how long folks were able to stick with this exercise regimen. But you've seen this in clinic when someone have their surgery, they have their chemotherapy, they've been so intimately involved with the oncology world, with the oncology practice, and they somehow feel that they're being let loose into this mean, angry world without any guidance and they're looking for something to do. “What more can I do in terms of my lifestyle?” And then here we have very solid data, as solid as can be for an intervention like exercise, showing that there is an impact and you can give a prescription for exercise when someone wraps up their chemotherapy for colon cancer, thanks to the study. Dr. Kristen Ciombor: Yeah. It was a great study. Dr. Shaalan Beg: Moving to gastroesophageal cancer, another late-breaking abstract. This is LBA5. The MATTERHORN trial was a phase 3 trial of durvalumab plus FLOT for resectable GE junction and gastric cancer. And again, another area where immunotherapy has made an impact, and here we're seeing it move closer for earlier-stage disease. What was your take-home for the MATTERHORN trial? Dr. Kristen Ciombor: Yeah, so this study looked at neoadjuvant perioperative durvalumab plus our current standard chemotherapy of FLOT versus placebo plus FLOT. And this was a large study, almost 1,000 patients were randomized. And the primary endpoint was event-free survival, and it was definitely met in favor of the D + FLOT arm, as Dr. Klempner discussed after Dr Janjigian's presentation. I do think there are still some unanswered questions here. Overall survival is not yet mature, so we do have to wait and see how that shakes out. But it's very interesting and kind of is reflective of what, as you said, we're looking at earlier and earlier lines of therapy, particularly with immunotherapy, in these GI cancer spaces. So it makes a lot of sense to test this and and to look at this. So the toxicity was pretty similar to what we would expect. Primary endpoint was met, but again, we'll have to wait and see what the survival data looks like. Dr. Shaalan Beg: Yeah, and in oncology, we know, especially for treatment that does add additional cost, it does add additional potential toxicity that we want to see that overall survival nudged. I did see some polls on social media asking folks whether their practices changed from this, and I think the results were favoring adding durvalumab for this group of patients but understanding that there are caveats to the addition of treatments and the eventual FDA approval in that indication as well. Dr. Kristen Ciombor: Exactly. I completely agree with that. Dr. Shaalan Beg: All right. How about we stick with gastroesophageal cancer? LBA4002 was trastuzumab deruxtecan versus ramucirumab plus paclitaxel for second-line treatment in HER2-positive unresectable or metastatic gastric cancer or GE junction cancer. This was the DESTINY-Gastric04 study. And again, antibody-drug conjugates making a big impact across different diseases. And here we have more data in the HER2-positive gastric cancer space. Your thoughts on this study? Dr. Kristen Ciombor: Yeah, so this is a really important space in gastroesophageal cancer because the HER2 positivity rate is fairly high as compared to some of our other tumor types. So, I do think one of the important things was that patients did have biopsy confirmation of HER2 status, which was very important, and then they were randomized to either T-DXd versus the kind of second-line standard of ramucirumab-paclitaxel. So this was a great practical study and really answers a question that we had for a while in terms of does anti-HER2 therapy in the second-line really impact and improve survival. So we did see a statistically significant improvement favoring T-DXd. I do think it's always important to look at toxicity, though, too. And there was about almost 14% rate of interstitial lung disease, which of course is the most feared toxicity from some of these antibody-drug conjugates, especially T-DXd. So I do think it's important to keep that in mind, but this is definitely a great addition to the armamentarium for these HER2-positive patients. Dr. Shaalan Beg: And pancreas cancer was on the stage after a very long time with a positive clinical trial. This is Abstract 4006. These were preliminary results from a phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel alone for previously untreated metastatic pancreas cancer. This is a frontline clinical trial of gemcitabine/nab-paclitaxel plus/minus the study drug. There were other cohorts in this study as well, but they reported the results of their part 3B arm. And great to see some activity in the pancreas space. And your thoughts? Dr. Kristen Ciombor: Yeah, we definitely need better treatments in pancreas cancer. This was a very welcome presentation to see. The elraglusib is an inhibitor of GSK-3beta, and it's thought that that mediates drug resistance and EMT. And so this is, I think, a perfect setting to test this drug. So patients basically were randomized. Patients with metastatic pancreas cancer were randomized 2: 1 to gemcitabine/nab-paclitaxel plus or minus this elraglusib. So, what we saw was that overall survival was better with the addition of this new drug. And overall, not only the 1-year overall survival, but also median overall survival.  The thing that was interesting, though, was that we saw that the overall survival rates were 9.3 months with the combination versus 7.2 months with just gemcitabine/nab-paclitaxel. And that's a little bit lower than we've seen in other studies. So, not sure what was going on there. Was it the patients that were a bit sicker? Was it a patient selection, you know, thing? I'm not really sure how to explain that so much. Also, the toxicity profile was much higher in terms of visual impairment, with over 60% of patients being treated with the combination versus 9% with gemcitabine/nab-paclitaxel. So these were mild, grade 1 and 2, but still something to be cautious about. Dr. Shaalan Beg: And especially with this being a phase 2 trial, making sure that in a larger study we're able to better evaluate the toxicity and see if the control arm in the larger confirmatory study performs differently will be really important before this compound makes it to the clinic in our space. But very exciting to see these kinds of results for pancreas adenocarcinoma. Dr. Kristen Ciombor: Yeah. Dr. Shaalan Beg: We've talked, it seems, a couple of times on this podcast about the BREAKWATER clinical trial. We did hear PFS and updated OS data, updated overall survival data on first-line encorafenib plus cetuximab plus modified FOLFOX6 for BRAF-mutated colorectal cancer. This was LBA3500. And eagerly anticipated results – we have all previously heard the progression-free survival results – but here we heard updated overall survival results, and very well-received study it seemed from the audience that time. So what are your takeaways on the updated results for BREAKWATER? Dr. Kristen Ciombor: In my opinion, this was one of the most practice-confirming studies. As you mentioned, we've already seen some of the preliminary data of BREAKWATER at prior meetings. But really what was particularly impactful for me was the median overall survival with the BREAKWATER regimen. So, again, patients received FOLFOX, encorafenib cetuximab in the first line if they had BRAF-mutated V600E-mutated colorectal cancer. And the median PFS was 12.8 months, which was actually really remarkable in this traditionally very aggressive, poor prognosis subtype of tumors. So, by seeing a median overall survival of 30.3 months was just incredible, in my opinion. Just a few years ago, that was considered the median overall survival for all comers for metastatic colorectal cancer. And we know the median overall survival was more in the less than 12 months range for BRAF. So this was incredibly impactful, and I think should be absolutely practice-changing for anyone who is eligible for this regimen.  I think again, where the practice meets the study is what's kind of important to think about too, how long did patients get FOLFOX, and certainly it adds toxicity to add a BRAF-targeted regimen on top of FOLFOX already. So, one of the other interesting things about the study, though, was that even though it didn't complete treatment, they actually did look at encorafenib/cetuximab alone and in the first line without chemotherapy. And those preliminary results actually looked okay, especially for patients who might not be able to tolerate chemotherapy, which we certainly see in practice. So, overall, definitely more data. And I agree that it's certainly practice-changing. Dr. Shaalan Beg: And it completely, as you mentioned, changes the outlook for a person who's diagnosed with BRAF-mutated metastatic colon cancer today versus even 7 or 8 years ago. Dr. Kristen Ciombor: And we're seeing this over and over in other subtypes too, but how you choose to treat the patient up front really matters. So really giving the right regimen up front is the key here. Dr. Shaalan Beg: And along the same lines, Abstract 3501 wanted to answer the question on whether people with MSI-high metastatic colorectal cancer need double checkpoint inhibitor therapy or is single therapy enough. So this [CheckMate-8HW] study compared nivo plus ipi with nivo alone, nivo monotherapy for MSI-high metastatic colorectal cancer. And we've known that both of these are fairly active regimens, but we also know the chance of immune-related adverse events is significantly higher with combination therapy. So this was a much-needed study for this group of patients. And what were your takeaways here? Dr. Kristen Ciombor: This, of course, has been really nivo-ipi in the first-line MSI-high metastatic colorectal cancer is now a standard of care. And not everybody is eligible for it, and there could be reasons, toxicity reasons, and other things too. But as we've been seeing for the last couple of years, immunotherapy clearly beats chemo in this space. And now looking at doublet versus single immunotherapy treatment in the first line, I think really nivo-ipi does beat out monotherapy. I will say, however, there is a caveat in that we still haven't seen the nivo-ipi versus nivo in the first line. So what has been presented thus far has been across all lines of therapy, and that does muddy the waters a little bit. So definitely looking forward and and we've asked this many times and based on the statistical plan and and what not, you know, we just haven't seen that data yet. But I do think it's becoming increasingly important to consider doublet immunotherapy for these patients as long as there are no contraindications. With the again, with the caveat that we have to have these toxicity discussions in the clinic with patients because many patients can tolerate it, you know, this regimen fairly well, but there can be very severe toxicities. So, I think an informed discussion should really be had with each patient before moving forward. Dr. Shaalan Beg: Yeah, informed decision, making them aware of the potential of real significant toxicities, immune-related toxicities with double therapy. But I am curious in your practice, how often do you see people choosing doublet therapy as frontline? Dr. Kristen Ciombor: So patients are really savvy, and a lot of times they've heard this data before or have come across it in patient advocacy groups and other things, and it's really nice to be able to have that conversation of the risk versus benefit. So I will say not all of my patients choose doublet, and many of them are still cured with immunotherapy monotherapy. So the big question there is, will we ever understand who actually needs the doublet versus who can still be cured or have very good long-term outcomes with just the single agent? And that has not been answered yet. Dr. Shaalan Beg: What a great point. So the last abstract I was hoping we could talk about is POD1UM-303 or the INTERAACT2 subgroup analysis and impact of delayed retifanlimab treatment for patients with squamous cell carcinoma of the anal canal. What were your thoughts here? Dr. Kristen Ciombor: This was a study, actually we saw at ESMO, we saw the primary data at ESMO last year, and this was an update with some exploratory analyses. But this was really an important study because once again, we're looking at immunotherapy in later lines of therapy. That's how we started looking at and investigating immunotherapy, and now we're moving it up and up in the treatment course. So this was a study of carboplatin/paclitaxel plus or minus retifanlimab. Actually it was retifanlimab versus placebo. And it was a positive study, as we heard last year. This actually led to FDA approval of this regimen last month, just before ASCO, and it has now been incorporated in the NCCN guidelines as the preferred first-line option.  So what I thought was important from the additional data presented at ASCO was looking at the different subgroups, it did not appear that patients with liver mets or not had different outcomes. So that was really good to see because sometimes in colon cancer we see that immunotherapy doesn't work as well when patients have liver mets. And interestingly, because we use immunotherapy in anal cancer without any biomarkers, unlike with colon cancer or some of the other tumor types, also the authors looked at PD-L1 status, and it did look like maybe patients did a little bit better if they had higher PD-L1 expression, but patients still could benefit even if they were PD-L1 negative. So that was important, I think, and we will continue to see further data come out from this study. I want to mention also that EA2176 just completed accrual, so that was carbo-taxol plus or minus nivolumab. And so we should be seeing that data sometime soon, which will hopefully also confirm the ongoing role for immunotherapy in the first-line setting for anal cancer. Dr. Shaalan Beg: That was a fantastic review. Thank you, Dr Ciombor. Thanks for sharing your valuable insights with us today on the ASCO Daily News Podcast. Dr. Kristen Ciombor: Thanks for having me here. Dr. Shaalan Beg: And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode. And if you value the insights that you hear on the podcast, please take a moment to rate, review, and subscribe, wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Shaalan Beg  @ShaalanBeg  Dr. Kristen Ciombor @KristenCiombor Follow ASCO on social media:    @ASCO on Twitter   @ASCO on BlueSky  ASCO on Facebook    ASCO on LinkedIn    Disclosures:   Dr. Shaalan Beg:   Consulting or Advisory Role: Ipsen, Cancer Commons, Foundation Medicine, Science37, Nant Health, Lindus Health Speakers' Bureau: Sirtex Research Funding (Inst.): Delfi Diagnostics, Universal Diagnostics, Freenome Dr. Kristen Ciombor: Consulting or Advisory Role: Pfizer, Incyte, Exelixis, Bayer, ALX Oncology, Tempus, Agenus, Taiho Oncology, Merck, BeiGene Research Funding (Inst.): Pfizer, Boston Biomedical, MedImmune, Onyx, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Incyte, Amgen, Sanofi, Bristol-Myers Squibb, Array BioPharma, Incyte, Daiichi Sankyo, Nucana, Abbvie, Merck, Pfizer/Calthera, Genentech, Seagen, Syndax Travel, Accommodations, Expenses: Incyte, Tempus

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

Minor Disaster Games is a family business created by brothers Kristian and Liam as the design team, and Kristian's wife Caley taking on the business and operation of the company. Their first game, Trouble On The Tempus is a co-op time travelling disaster management game.Kristian is a writer, filmmaker, gamer, and all round creative scatterbrain who is always working on some project or other. He began working on "Trouble on the Tempus" over ten years ago just for fun and the project has slowly evolved into what is now Minor Disaster Games. He also has been working on his YouTube channel KristiansBrain since 2022 and many videos about the game can be found there.To learn more about Trouble on the Tempus, click here: www.kickstarter.com/projects/kristiansbrain/trouble-on-the-tempus WHERE TO BUY OUR BOOK: https://www.amazon.com/dp/B0DSJ1LMQ1FOLLOW US ON: Facebook: https://www.facebook.com/groups/boardgamebingeInstagram: https://www.instagram.com/boardgamebingepodcast/ Twitter: https://www.twitter.com/boardgamebingeWHERE TO FIND OUR PODCAST:Spotify: https://open.spotify.com/show/5RJbdkguebb3MSLAatZr7riHeart Radio: https://www.iheart.com/podcast/269-board-game-binge-72500104/Tune In: https://tunein.com/embed/player/p1344218/Google Podcasts: https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5jYXB0aXZhdGUuZm0vYm9hcmRnYW1lYmluZ2U=Apple Podcasts: https://podcasts.apple.com/ca/podcast/board-game-binge/id1522623033Visit Our Websites: Board Game Binge: https://boardgamebinge.com/Tin Robot Games: https://tinrobotgames.comElixir Board Games: https://www.elixirboardgames.com/our-games

When a simple podcast celebrating Batman Forever's 30th anniversary is interrupted by the likes of HG Wells and the dastardly Tempus, our crack team of writers must drop everything for 2-ish hours and pitch the greatest Lois & Clark/Batman Forever crossover TV movie they can possibly imagine… within the city limits of 90s Metropolis, of course. Check out this week's guests on all their other great podcasts: Zach Moore: Always Hold On To Smallville Lance Laster: Always Hold On To Arrow Kevonte Chilous: Always Hold On To Star Wars and for no real reason… Rob O'Connor: All Star Superfan Podcast Matt Truex is a Warner Bros. Discovery employee. The views and opinions expressed in this podcast are his own and do not necessarily reflect the views or positions of Warner Bros. Discovery.

The HuSTLe City Heroes continue to give STL artist Bo Dean his flowers as they review his recent show he headlined Tempus Meminisse which is Latin for A Time to Remember.

Un triple CD como banda sonora del libro del pianista, crítico de jazz y musicólogo francés Laurent Cugny, antiguo director de la Orquesta Nacional de Jazz y profesor emérito de la Sorbona, 'Une histoire du jazz': Original Dixieland Jazz Band ('Tiger rag'), King Oliver´s Creole Jazz Band ('Canal street blues'), Jelly Roll Morton Red Hot Peppers ('Black bottom stomp'), Louis Armstrong & His Hot Five ('Hotter than that'), Bix Beiderbecke Wolverine Orchestra ('Jazz me blues'), Fletcher Henderson ('New king porter stomp'), Lester Young ('These foolish things'), Count Basie and His Orchestra ('Jumpin´at the woodside'), Duke Ellington and His Orchestra ('Echoes of Harlem'), Benny Goodman Orchestra ('Clarinet a la king'), Dizzy Gillespie and His All Stars ('Hot house'), Charlie Parker Ribop Boys ('Roko'), Bud Powell ('Tempus fugit'), Miles Davis Nonet ('Boplicity'), The Stan Getz Quintet ('Thou swell'), Chet Baker Quartet ('I fall in love') y Dave Brubeck ('Take five').Escuchar audio

In this episode, Scott Becker discusses Tempus AI's rapid growth, recent market moves, and its impact on oncology care.

► If you enjoyed the episode, please leave us a good review!► More from PIF: https://linktr.ee/practicalislamicfinanceTempus made a HUGE mistake! Down 20%In this episode, we will cover:IntroTempus AI Down 20%Why Management's Silence Is a Huge MistakeBackground on Tempus AIResponse to Short Report: CEO Track RecordCriticism of AI Revenue ContributionBusiness Model ExplainedAllegations of Aggressive AccountingValuation Analysis and Free Cash Flow ConcernsFinal Verdict on Tempus AIQ&A: Apple, Canon, Mining Stocks CONTACT USsalam@practicalislamicfinance.comABOUT OUR PODCASTOur podcast is about helping people ethically build wealth. We cover a broad range of topics, including stock and crypto investing, product reviews, and general financial well-being.DISCLAIMERAnything you hear in this video is an opinion. It is not personalized financial advice. Make sure you do your due diligence before making any investment decisions.

Kara Werner, VP & GM at Tempus AI, joins Kellogg MBA student Ashley Lemon to discuss how Tempus makes patient data meaningful - enabling earlier cancer diagnoses and accessible precision medicine. They also discuss Kara's career journey at the healthtech startup and advice for MBAs looking to break into the space.LinkedInTimestamps:(1:47) Kara's why: from Kellogg to Tempus AI(4:17) Fixing what's broken: structuring and operationalizing multimodal patient data(10:08) Tempus's edge: RNA & DNA, AI-enabled diagnostics platform & strategic partnerships (14:58) AI in action: how Tempus One, Lens & Next connect patients to trials and testing to close care gaps(18:27) Standing up pharma biz: building and adapting for a new client(26:02) What Kara's excited about: tissue-sparing RNA for identifying ADC candidates(28:55) MBA advice: taking Medvec's Negotiations, welcoming challenge, pivoting with purpose(36:24) Wildest & craziest dream: travel experience curator!Visit our podcast page for more episodes on trends and innovation in healthcare and follow our socials so you never miss an update.

In this episode, Scott Becker discusses Tempus AI's rapid growth, recent market moves, and its impact on oncology care.

In this episode, Scott Becker discusses Tempus AI's rapid growth, recent market moves, and its impact on oncology care.

The UK Games Expo 2025 is nearly here, and Matt, Karen, and Rai are back with their annual mega-preview! In this episode, the team covers everything you need to know for UKGE 2025 – from the new hall layout and bring & buy changes, to Chow Street's food truck lineup and their top tips for surviving the weekend.They also each highlight five games they're excited to see at the show, including upcoming releases like Trouble on the Tempus, Restless Spirits, Fathom, Pergola, The Last Week of Summer, Popcorn, Gwent: The Card Game, and many more.Whether you're prepping your spreadsheets or just curious what to keep an eye on, this is your essential guide to UKGE 2025!

In Episode 101, Matt and Karen return for a slightly shorter show ahead of their big UKGE preview. They share highlights from recent game days with friends, discussing a mix of new and favourite titles, including Rebirth, Restless Spirits, Trio, Castle Combo, Explorers of Navoria, and more.Matt also interviews the team behind Minor Disaster Games, creators of the upcoming Kickstarter for Trouble on the Tempus—a co-op, time-travelling disaster management game. The team dives into the game's origins, inspirations, and what sets it apart in the crowded co-op space.

Semaine #20. Chaque lundi matin nous servons le SILEXpresso, un condensé vocal de 5mn sur nos vues macro et allocation.  Retrouvez également le SILEXpresso, et bien plus encore, sur l'app SPARK :https://go.silex-partners.com/download/my_SPARK_appHosted by Ausha. See ausha.co/privacy-policy for more information.

Deeper Dive into Ironman Texas ahead of the North American ChampionshipIntro (0:00-03:30)Ventum and the new Tempus (03:35- 10:45)Women's Race Dynamics and Predictions (10:50-38:25)Men's Race Dynamics and Predictions (38:30-57:45)Fan Hot Takes (57:50-1:10:00)Subscribe on Youtubehttps://www.youtube.com/@protrinewsFollow the link below to get yourself a new bike, built to break recordshttps://ventumracing.com/products/tempus/?srsltid=AfmBOoopQyZfAU8TmsQM2xBqsG3GoxOleNRHT8VKxApiU1xbKhspD4ZJGet a tasty box from MNSTRY Nutrition! Use code ProTri50https://mnstry.com/en/products/tastingboxCapture your next race or event experience with Crowd Clips https://crowdclips.com/Buy a gear. 15% off with Protrinews15https://wynrepublic.comDisclaimer: The contents and opinions expressed on this podcast are ultimately exaggerated (often wildly) for comedic effect. All opinions presented are for entertainment purposes only. Any statements seeming to refer to any specific person, place, institution, or event are probably not about it or you and almost impossible to prove legally, anyway. It might be you, but probably not and nobody really cares. Especially you. It's not always about you.Support the show

This month, Duane and Scott explore the history of “Good King Wenceslas”.Versions played in the episode:Blackmore's NightThe Irish RoversChris HendricksTori AmosReggae All-StarsStan Kenton Jazz OrchestraMatthew Green's Orchestral RainbowMannheim SteamrollerOdynHere's the link to the poll to vote for your favorite song from this episode:https://pollforall.com/p346dormHere's the clip from “Love Actually”:https://www.youtube.com/watch?v=M4-35TN6AmwThis is the 13th century spring carol “Tempus dest Floridum” that gave us the melody for Good King Wenceslas:https://www.youtube.com/watch?v=zv8PgukSLX0From listener Bob in Utah, here's the link to the Majestica album “A Christmas Carol”:https://youtu.be/nq5No8qsowA?si=Y37SJX4F5g4w5cE4From listener Steve Banks, here's a the reggae playlist “Reggae Christmas Parade”:https://open.spotify.com/playlist/2ZH6rGilSmg9p4VxF2ubkU?si=IMf_S2cuSGyMYHqwDxPp7Q&pi=AO2eqAlHT0SeM&nd=1&dlsi=5cc261712ab14247

In this insightful episode of FYI, Eric Lefkofsky, CEO of Tempus, shares his journey from leading tech companies like Groupon to pioneering innovation in healthcare through AI. Lefkofsky explains how Tempus integrates advanced technology into medical diagnostics, making healthcare more precise and data-driven. He discusses the challenges of the U.S. healthcare system, the power of AI in personalized medicine, and the critical role of bridging gaps between technology and biology. Discover how Tempus is revolutionizing oncology and expanding its reach to other medical fields through strategic AI applications.Key Points From This Episode:How Eric Lefkofsky transitioned from tech to healthcare innovation.The story behind Tempus' founding and its mission to personalize patient care.How Tempus uses AI to connect diagnostics with real-time clinical data.The systemic barriers in U.S. healthcare and how Tempus overcomes them.Key insights on the future of AI in precision medicine and its potential to transform patient outcomes.

Además de los cantos propios de la semana 8ª del Tempus per Annum vamos a dedicar el programa a Louis Jambou, hispanista francés recientemente fallecido. Sus estudios sobre el mundo ibérico, en especial sobre el órgano, contribuyeron a un mejor conocimiento del instrumento y de las formas musicales de su repertorio. En su memoria escucharemos diversas piezas de órgano alternatim con canto llano.Escuchar audio

In this insightful episode of FYI, Eric Lefkofsky, CEO of Tempus, shares his journey from leading tech companies like Groupon to pioneering innovation in healthcare through AI. Lefkofsky explains how Tempus integrates advanced technology into medical diagnostics, making healthcare more precise and data-driven. He discusses the challenges of the U.S. healthcare system, the power of AI in personalized medicine, and the critical role of bridging gaps between technology and biology. Discover how Tempus is revolutionizing oncology and expanding its reach to other medical fields through strategic AI applications.Key Points From This Episode:How Eric Lefkofsky transitioned from tech to healthcare innovation.The story behind Tempus' founding and its mission to personalize patient care.How Tempus uses AI to connect diagnostics with real-time clinical data.The systemic barriers in U.S. healthcare and how Tempus overcomes them.Key insights on the future of AI in precision medicine and its potential to transform patient outcomes.

What a pleasure to welcome today's guest, Ryan Fukushima, chief operating officer of TempusAI. Not only has Ryan helped build Tempus brick by brick from the earliest days, he is also CEO of Pathos AI, a biotech company using real world data and AI to develop true precision medicines. I don't know how he juggles it all, but unless you've been hiding out these last few years, Tempus has become a household name in our industry, completing a highly successful IPO last year. But no need to take my word for it, come on in and have a listen!TPM E43 highlights >⁠⁠⁠⁠⁠⁠Episode 43 links:Ryan Fukushima on LinkedIn⁠⁠Tempus AI⁠⁠Pathos⁠⁠Tempus announces multi-year collaboration with Genialis

Help our Guild brother Leo avoid homelessness and get back on his feet: https://gofund.me/04836d64 The Meaning of Catholic is a collaborative lay apostolate dedicated to uniting Catholics against the enemies of holy Church through the domestic church, catechetics, and the public promotion of truth and charity. https://meaningofcatholic.com/ -Confession of Faith: https://meaningofcatholic.com/my-confession-of-faith/ -Internet Promise: https://meaningofcatholic.com/my-promise/ Join the Guild to support our work and access the online community, free books, and exclusive content: https://meaningofcatholic.com/register or donate: http://meaningofcatholic.com/donate or if you can't afford to join and would like free membership, contact us: https://meaningofcatholic.com/contact Join our lay sodality which offers up penance for clergy and seminarians: https://meaningofcatholic.com/2022/03/01/fellowship-st-anthony/

Seguimos escuchando los cantos propios de la semana 7ª del Tempus per Annum y aprovechamos la fiesta de hoy, la cátedra de san Pedro con algunos de sus cantos específicos. De manera extraordinaria escucharemos el motete de Francisco Guerrero Petre, ego pro te rogavi compuesto para esta fiesta y la misa que sobre esta pieza compuso su alumno, el también sevillano Alonso Lobo.Escuchar audio

n this episode, Scott Becker highlights the impressive 150% year-to-date rise of Tempest AI, founded by a financial genius and Illinois' wealthiest resident.

n this episode, Scott Becker highlights the impressive 150% year-to-date rise of Tempest AI, founded by a financial genius and Illinois' wealthiest resident.

Vamos avanzando ya hacía la cuaresma y junto a los cantos de la semana 6ª del Tempus per Annum, escucharemos músicas de las celebraciones de los Santos de esta semana, añadiendo además una infrecuente grabación dedicada a la liturgia de san Adalberto, patrono de Polonia a cargo de la Lektorska Schola Cantorum.Escuchar audio

In this episode, Scott Becker discusses three stocks chosen by one of his favorite stock pickers.

In this episode, Scott Becker discusses three stocks chosen by one of his favorite stock pickers.

Post colloquium praeritum de novis consiliis anni 2025, in ipso colloquio nos interrogabamus.. quid faceremus si nobis tempus liberum esset? si vere ea quae semper facere voluistis nec unquam satis temporis est sponte facere liceret? Ecce ea quae nos excogitavimus! quid vos faceretis?Lidae nunquam satis linguarum sunt! Quid si dies triginta horarum haberemus? Quid faceretis vos?

Mediæ Ætatis Sodalicium, el coro de monjas benedictinas del monasterio de Kellenreid y la Schola Gregoriana Monacensis nos proporcionan las sonoridades de las santas Águeda y Escolástica junto a los cantos propios de la semana 5ª del Tempus per Annum.Escuchar audio

Tonight on Market Mondays, we broke down the truth about the DeepSeek situation and shared our thoughts on the developments since last week. We also discussed six stocks that could be DeepSeek-proof for those concerned about a potential AI or chip sector crash. With Nvidia's earnings on the horizon, we explored whether the company needs to blow out expectations to keep the stock market afloat.We also took a deep dive into Tempus as a long-term investment, especially now that Nancy Pelosi has revealed she's trading it. The conversation then shifted to the impact of tariffs on the market, particularly semiconductor stocks, and which companies could benefit from these changes. As AI and tech continue to evolve, we discussed how we can better prepare our youth to compete in this rapidly changing space. Another key topic was the recent wave of hedge funds selling off stocks—what it means and how investors should respond. Additionally, we highlighted a few stocks we like under $100 and addressed the burning question: Should investors consider selling Nvidia?To close out the episode, we sat down with Timbaland for a powerful conversation about the state of music, AI's growing influence in the industry, the importance of independence, and key lessons from some of the greatest artists of all time.#MarketMondays #DeepSeek #AIStocks #Nvidia #StockMarket #Investing #TechStocks #HedgeFunds #Timbaland #MusicIndustry #AI #FinanceSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

In this week's episode of the Inside EMS Podcast, hosts Chris Cebollero and Kelly Grayson discuss some of the biggest news stories in EMS from the month. First up: A fire chief in Colorado is under investigation for running nearly 300 medical calls on an expired paramedic certification from 2019. What happens when leadership sets a bad example for their crews? The pair also discuss several mental health initiatives, including the University of Washington's new first responder training program and the mental health teams supporting evacuees of California's wildfires. Plus, Chris reacts to an idea floated by the new White House administration to reduce FEMA's role, and Kelly gives his take on why the agency – despite its flaws – is a necessity. Have an EMS-related news story you want Chris and Kelly to analyze? Send an email to theshow@ems1.com. Memorable quotes  “If you don't want to pay for it, then, then don't gripe about poor response times ... or inadequate care, because you wouldn't pay for it.” — Kelly Grayson “ You know, during COVID, we were heroes.  And we squandered that goodwill and let ourselves be pushed onto the back burner until something horrific happens to California. And then firefighting leaps into the breach again. Then, those citizens are incredibly grateful, but when this is all over, they'll fade back into obscurity again.” — Kelly Grayson This episode of the Inside EMS Podcast is sponsored by Philips. Time to take pre-hospital emergency care to the next level. Time for Tempus. Enjoying the show? Contact the Inside EMS team at theshow@ems1.com to share ideas, suggestions and feedback, or let us know if you'd like to join us as a guest. 

Dive into the explosive world of dance with Loren Dermody and Derek Piquette as they unpack the groundbreaking Prodigy Dance Convention and the rising importance of acro in performance. From viral University of Minnesota routines to insights from UDA Nationals, this episode reveals why dance teams are transforming the performing arts landscape. Get the inside scoop on the upcoming Accelerate Acro Convention and discover how acro skills are revolutionizing dance, commercials, and professional performances. Tune in for an electrifying journey through the future of movement! About Derek Piquette Derek Piquette, a multifaceted artist from Chicopee, MA, began his dance journey at 10. A principal dancer in Carmen and The Maid, he gained recognition on Season 12 of So You Think You Can Dance, finishing top 4 and touring. Derek founded Intrepid Dance Company in 2017, directing and choreographing its debut, "HER." Starring as the "Trickster" in Cirque Du Soleil's KOOZA, Derek also reached the finals on NBC's World Of Dance Season 3. As a teacher and choreographer, Derek contributed to renowned organizations like CLI Studios and judged competitions. Choreographing 350+ award-winning pieces since 2014, he left a mark on Dance Moms, Disney Channel's Backstage, and So You Think You Can Dance. Derek's passion extends to mentoring young dancers globally, leaving a lasting impact through his exceptional teaching approach and inspiring them to excel in dance. Follow Derek on IG: https://www.instagram.com/derekpiquette/ Prodigy Dance Convention: https://www.prodigydanceconvention.com/ Accelerate Acro Convention: https://accelerateacroconvention.com/ If you'd like more amazing content more tips and ideas check out our Acrobatic Arts Channel on YouTube. Subscribe Now! Connect with Acrobatic Arts on your favourite social media platform: Instagram: https://www.instagram.com/acrobaticarts/ Facebook: https://www.facebook.com/Acroarts Twitter: https://twitter.com/acrobatic_arts/ Learn more and register for our programs at AcrobaticArts.com

In this episode, Scott Becker shares insights into Tempus AI’s 35% stock surge, and the brilliance of its founder, Eric Lefkofsky.

In this episode, Scott Becker shares insights into Tempus AI’s 35% stock surge, and the brilliance of its founder, Eric Lefkofsky.

The Fellstar pirates and Tempus take on Helsif, the Unending Cyclone in the penultimate fight to recover Oghma and the Gilded Way. But just when things seem to be winding down, an old foe makes a surprise reappearance.

In this episode, Scott Becker discusses five key market stories.

In this episode, Scott Becker discusses five key market stories.

Galva's first encounter with a real giant does not go her way, in any capacity. The Fellstar Pirates and Tempus clown their way through the underwater caverns of Galla'na in their quest to unseat Umberlee.

The Fellstar pirates and Tempus make the perilous trek over the crumbling, dangerous natural bridge known as The Shifting Expanse. --- Support this podcast: https://podcasters.spotify.com/pod/show/the-slaywrights/support

The final challenge at the top of the obelisk is a fight with Tempus himself. Once that's sorted out, the Fellstar pirates share their discovery with Elder Atsu, and a feast of celebration is prepared. --- Support this podcast: https://podcasters.spotify.com/pod/show/the-slaywrights/support

Locked inside the obelisk to Tempus, the Fellstar pirates enter a gauntlet of themed fights designed to test the might of those who wish to ascend to the top. --- Support this podcast: https://podcasters.spotify.com/pod/show/the-slaywrights/support

Will PhD students still exist in the future? This week, Autonomous Technology and Robotics Director of Research Sam Korus and Associate Portfolio Manager Nicholas Grous are joined by ARK Analyst Nemo Marjanovic to discuss the transformative potential of autonomous and decentralized science in drug discovery. Nemo discusses how AI and robotics are revolutionizing research processes, making them more efficient and cost-effective. The discussion also highlights the challenges faced in clinical trials and the role of blockchain technology in decentralizing research funding. The episode concludes with insights into the future of genomics and the innovative companies leading the charge in this space.If you know ARK, then you probably know about our long-term research projections, like estimating where we will be 5-10 years from now! But just because we are long-term investors, doesn't mean we don't have strong views and opinions on breaking news. In fact, we discuss and debate this every day. So now we're sharing some of these internal discussions with you in our new video series, “The Brainstorm”, a co-production from ARK and Public.com. Tune in every week as we react to the latest in innovation. Here and there we'll be joined by special guests, but ultimately this is our chance to join the conversation and share ARK's quick takes on what's going on in tech today.Key Points From This Episode:Autonomous science combines AI and robotics to enhance research and can significantly speed up the drug discovery process.Clinical trials represent the largest cost in drug development.Companies like Recursion and Tempus are leading innovations in genomics.The future of drug discovery may resemble an app store model.For more updates on Public.com:Website: https://public.com/YouTube: @publicinvestTwitter: https://twitter.com/public

Virginie Girod raconte le destin tragique du roi fantasque Louis II de Bavière.Le 13 juin 1886, dans la soirée, deux corps sont retrouvés flottants dans le lac de Starnberg, non loin du château de Berg, en Bavière. Quelques heures plus tôt, le roi Louis II (1845-1886) avait disparu alors qu'il se promenait avec son psychiatre, le Dr von Gudden. L'identification des cadavres confirme qu'il s'agit bien des deux hommes. Mais qu'est-il arrivé ? S'agit-il d'un suicide ? D'une dispute qui aurait mal tourné ?Louis II de Bavière hérite de la couronne de Bavière en 1864, à la mort de son père Maximilien II. Bientôt, ce grand amateur de musique et de théâtre, fou de l'art et l'être de Richard Wagner, est confronté à la guerre, qu'il tient en horreur. Mais peu enclin à gouverner, Louis II préfère faire construire de somptueux châteaux, multipliant les dépenses et suscitant la colère du peuple et de ses ministres. Quelques jours avant sa mort, il est déclaré inapte à gouverner pour cause de maladie mentale et interné dans une aile de son château de Berg. Au Cœur de l'Histoire est un podcast Europe 1.- Présentation : Virginie Girod- Ecriture : Frédéric Pennel- Production : Armelle Thiberge et Morgane Vianey- Réalisation : Nicolas Gaspard- Composition du générique : Julien Tharaud- Promotion et coordination des partenariats : Marie Corpet- Visuel : Sidonie Mangin BibliographieJacques Bainville, Louis II de Bavière, Texto, 2024Jean des Cars, Louis II de Bavière, Tempus, 2010

Virginie Girod raconte l'enfance du roi Louis XV dans un récit inédit d'Au cœur de l'Histoire.En 1712, une épidémie de rougeole décime les héritiers du Roi-Soleil vieillissant. Après avoir perdu le Dauphin, son petit-fils, il perd le duc de Bretagne, son arrière-petit-fils. Ne reste alors que le cadet de ce dernier, le duc d'Anjou, orphelin âgé de deux ans, qui, lui, survit miraculeusement à la maladie. Trois ans plus tard, alors que Louis XIV rend son dernier souffle, la couronne revient à celui que l'on appelle désormais Louis XV (1710-1774).Agé de cinq ans, Louis XV est alors trop jeune pour exercer pleinement ses fonctions. Préparé au pouvoir, il reçoit une éducation solide, dirigée par son gouverneur, le maréchal de Villeroy, et son précepteur, le cardinal de Fleury. Dès l'âge de dix ans, son tuteur, Philippe d'Orléans, régent du royaume, l'associe aux conseils de gouvernement. Confronté dès la jeune enfance à la mort, Louis XV développe un caractère mélancolique et sera, toute sa vie, accablé par la tristesse. Au Cœur de l'Histoire est un podcast Europe 1.- Présentation et écriture : Virginie Girod- Production : Armelle Thiberge et Morgane Vianey- Réalisation : Nicolas Gaspard- Composition du générique : Julien Tharaud- Promotion et coordination des partenariats : Marie Corpet- Visuel : Sidonie Mangin Bibliographie :François Bluche, Louis XV, Perrin, coll. Tempus, 2003Jean-Christian Petitfils, Louis XV, Perrin, coll. Tempus, 2021Ressources en ligne :Pascale Mormiche, “Enfance, enfances de princes en France (xviie-xviiie siècles)”, Mélanges de l'École française de Rome - Italie et Méditerranée modernes et contemporaines, 123-2 | 2011, 395-407 Louis XV - Site du château de Versailles Portrait de Charlotte Madeleine de la Mothe-Houdancourt, duchesse de Ventadour - Centre des Monuments nationaux

Remind yourself this morning and every morning: this will end. Tempus fugit.

Send us a textJoin us on this enlightening episode of the Living the Dream podcast with Curveball as we explore the world of visionary designer Ben Rousseau. Known for his emotion-driven, aesthetically captivating light installations and timepieces, Ben shares his journey from England's oldest recorded town to creating stunning experiences worldwide. Discover how his passion for lighting transforms spaces and touches human emotions. Plus, learn about his innovative projects like the Tempus timepiece collection and the unique 'Kiss My Art' gift box. Don't miss this inspiring conversation!Want to be a guest on Living the Dream with Curveball? Send Curtis Jackson a message on PodMatch, here: https://www.podmatch.com/hostdetailpreview/1628631536976x919760049303001600

In this episode, Scott Becker explores six trending stories, covering recent market gains, the influence of “the 3 T’s” (Trump, Tesla, and Thiel), and significant stock movements involving Tempus, NVIDIA, and Novo Nordisk.

In this episode, Scott Becker covers the election day’s market rally, discussing big stock moves from companies like Palantir, Tempus, and Berkshire Hathaway. He also touches on private equity milestones and offers some lighthearted reflections on his tennis game.

Ecoutez la suite du double récit inédit de Virginie Girod consacré à Josef Mengele, le médecin SS d'Auschwitz-Birkenau.Docteur en médecin et en anthropologie, Josef Mengele (1911-1979) adhère aux doctrines racistes propagées par le régime nazi, au pouvoir en Allemagne depuis 1933. Intégré à la SS à la fin des années 1930, il est affecté au camp d'Auschwitz-Birkenau en 1943. Celui qui a prêté le serment d'Hippocrate se livre alors à des expériences prétendument scientifiques sur des sujets humains. En 1946, après la défaite allemande, des médecins nazis ayant participé à l'extermination de millions de personnes sont jugés lors d'un procès organisés à Nuremberg. Mais Josef Mengele, le médecin d'Auschwitz, manque à l'appel.ATTENTION, cet épisode contient des descriptions susceptibles d'heurter la sensibilité de certains auditeurs.Thèmes abordés : Seconde Guerre mondiale, nazisme, médecine, expérimentations humaines, IIIe Reich Au cœur de l'Histoire est un podcast Europe 1- Présentation et écriture : Virginie Girod- Production : Armelle Thiberge et Morgane Vianey- Réalisation : Nicolas Gaspard- Composition des musiques originales : Julien Tharaud et Sébastien Guidis- Promotion et coordination des partenariats : Marie Corpet- Visuel : Sidonie Mangin Bibliographie :Franci Rabinek Epstein, La guerre de Franci, FlammarionBruno Halioua, Les médecins d'Auschwitz, PerrinGerald Steinacher, Les nazis en fuite, Perrin, coll. "Tempus"A voir :Emmanuel Amara, Josef Mengele, la traque d'un criminel nazi, Sunset production, 2017Ressources en ligne : Musée national Auschwitz-Birkenau La SS - Chemins de mémoire Pierre-André Taguieff, "Science nazie, science de mort", Mots. Les langages du politique, 1991 Josef Mengele - Encyclopédie multimédia de la Shoah Auschwitz, carte historique - Encyclopédie multimédia de la Shoah Les expériences médicales nazies - Encyclopédie multimédia de la Shoah Gerald Steinacher, Les nazis en fuite, Perrin, coll. "Tempus" A voir : Emmanuel Amara, Josef Mengele, la traque d'un criminel nazi, Sunset production, 2017 Ressources en ligne : Musée national Auschwitz-Birkenau https://www.auschwitz.org/en/history/ La SS - Chemins de mémoire https://www.cheminsdememoire.gouv.fr/fr/la-ss Pierre-André Taguieff, "Science nazie, science de mort", Mots. Les langages du politique, 1991 https://www.persee.fr/doc/mots_0243-6450_1991_num_27_1_1614 Josef Mengele - Encyclopédie multimédia de la Shoah https://encyclopedia.ushmm.org/content/fr/article/josef-mengele Auschwitz, carte historique - Encyclopédie multimédia de la Shoah https://encyclopedia.ushmm.org/content/fr/gallery/auschwitz-maps Les expériences médicales nazies - Encyclopédie multimédia de la Shoah https://encyclopedia.ushmm.org/content/fr/article/nazi-medical-experiments